Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. Bmj. 2024;384:e076743.
Google ScholarÂ
van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20:287–304.
Google ScholarÂ
Dyrskjøt L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.
Google ScholarÂ
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
Google ScholarÂ
Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018;19:e683–e695.
Google ScholarÂ
Lv Y, Song B, Yang G, Wang Y, Wu Z, Si M, et al. In situ transformable nanoparticle effectively suppresses bladder cancer by damaging mitochondria and blocking mitochondrial autophagy flux. Adv Sci. 2025;12:e2409425.
Google ScholarÂ
Ding Q, Tang W, Li X, Ding Y, Chen X, Cao W, et al. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer. J Control Release. 2023;363:221–34.
Google ScholarÂ
Abdullah KM, Sharma G, Anjum B, Alam MF, Yadav S, Singh Y, et al. Insulin resistance: The central node of convergence between unfolded protein response, diabetes, and cancer. Mol Asp Med. 2026;108:101458.
Google ScholarÂ
Oresta B, Pozzi C, Braga D, Hurle R, Lazzeri M, Colombo P, et al. Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. Sci Transl Med. 2021;13:eaba6110.
Google ScholarÂ
Viale A, Corti D, Draetta GF. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015;75:3685–6.
Google ScholarÂ
Zhou D, Sun MH, Jiang WJ, Li XH, Lee SH, Heo G, et al. Knock-down of YME1L1 induces mitochondrial dysfunction during early porcine embryonic development. Front Cell Dev Biol. 2023;11:1147095.
Google ScholarÂ
He J, Shangguan X, Zhou W, Cao Y, Zheng Q, Tu J, et al. Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development. Nat Commun. 2021;12:4371.
Google ScholarÂ
Xin W, Zhou J, Peng Y, Gong S, Liao W, Wang Y, et al. SREBP1c-mediated transcriptional repression of YME1L1 contributes to acute kidney injury by inducing mitochondrial dysfunction in tubular epithelial cells. Adv Sci. 2025;12:e2412233.
Google ScholarÂ
Guo YZ, Chen G, Huang M, Wang Y, Liu YY, Jiang Q, et al. TIMM44 is a potential therapeutic target of human glioma. Theranostics. 2022;12:7586–602.
Google ScholarÂ
Xia Y, He C, Hu Z, Wu Z, Hui Y, Liu YY, et al. The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth. Int J Biol Sci. 2023;19:1778–90.
Google ScholarÂ
MacVicar T, Ohba Y, Nolte H, Mayer FC, Tatsuta T, Sprenger HG, et al. Lipid signalling drives proteolytic rewiring of mitochondria by YME1L. Nature. 2019;575:361–5.
Google ScholarÂ
Sun X, Shi C, Dai J, Zhang MQ, Pei DS, Yang L. Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo. Cell Death Dis. 2024;15:346.
Google ScholarÂ
Kolch W, Halasz M, Granovskaya M, Kholodenko BN. The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer. 2015;15:515–27.
Google ScholarÂ
Oh E, Akopian D, Rape M. Principles of ubiquitin-dependent signaling. Annu Rev Cell Dev Biol. 2018;34:137–62.
Google ScholarÂ
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer. 2024;23:148.
Google ScholarÂ
Tong Y, Wang Z, Wang Y, Chen Y, Zhang H, Lu Y, et al. The E3 ubiquitin ligase ARIH1 facilitates colorectal cancer progression by promoting oxidative phosphorylation via the mitochondrial translocation of K63-linked ubiquitinated PHB1. Adv Sci. 2025;12:e2501017.
Google ScholarÂ
Hunkeler M, Jin CY, Fischer ES. Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases. Science. 2023;379:1105–11.
Google ScholarÂ
Li T, Li Y, Liu T, Hu B, Li J, Liu C, et al. Mitochondrial PAK6 inhibits prostate cancer cell apoptosis via the PAK6-SIRT4-ANT2 complex. Theranostics. 2020;10:2571–86.
Google ScholarÂ
Dudley-Fraser J, Esposito D, McPhie KA, Morley-Williams C, Auchynnikava T, Rittinger K. Identification of RING E3 pseudoligases in the TRIM protein family. Nat Commun. 2025;16:3456.
Google ScholarÂ
Yamada Y, Kimura N, Maki K, Hakozaki Y, Urabe F, Kimura S, et al. The roles of tripartite motif proteins in urological cancers: a systematic review. Cancers. 2025;17:2367.
Google ScholarÂ
Fan X, Dai Y, Mo C, Li H, Luan X, Wang B, et al. TRIM21 promotes tumor growth and gemcitabine resistance in pancreatic cancer by inhibiting EPHX1-mediated arachidonic acid metabolism. Adv Sci. 2025;12:e2413674.
Google ScholarÂ
Liu J, Zhang C, Xu D, Zhang T, Chang CY, Wang J, et al. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer. J Clin Investig. 2023;133:e164354.
Google ScholarÂ
Zhu X, Xue J, Jiang X, Gong Y, Gao C, Cao T, et al. TRIM21 suppresses CHK1 activation by preferentially targeting CLASPIN for K63-linked ubiquitination. Nucleic Acids Res. 2022;50:1517–30.
Google ScholarÂ
Yao D, Xin F, He X. RNF26-mediated ubiquitination of TRIM21 promotes bladder cancer progression. Am J Cancer Res. 2024;14:4082–95.
Google ScholarÂ
Tsai YS, Jou YC, Tsai HT, Shiau AL, Wu CL, Tzai TS. Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer. Cancer Sci. 2019;110:1208–19.
Google ScholarÂ
Wei WS, Wang N, Deng MH, Dong P, Liu JY, Xiang Z, et al. LRPPRC regulates redox homeostasis via the circANKHD1/FOXM1 axis to enhance bladder urothelial carcinoma tumorigenesis. Redox Biol. 2021;48:102201.
Google ScholarÂ
Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29:725–38.
Google ScholarÂ
Yamashita SN, Tanaka Y, Islam S, Kitagawa T, Tokuda K, Paudel D, et al. Expression of YME1 like 1 ATPase increases with the stage of adrenocortical carcinoma tissue and is associated with poor patient prognosis. Anticancer Res. 2026;46:1577–82.
Google ScholarÂ
Anand R, Wai T, Baker MJ, Kladt N, Schauss AC, Rugarli E, et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J Cell Biol. 2014;204:919–29.
Google ScholarÂ
Ando K, Yokochi T, Mukai A, Wei G, Li Y, Kramer S, et al. Tumor suppressor KIF1Bβ regulates mitochondrial apoptosis in collaboration with YME1L1. Mol Carcinog. 2019;58:1134–44.
Google ScholarÂ
